Prevention study enrolling women ages 25-55 with a BRCA1 mutation
This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.
Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.
Latinas with a high risk of breast cancer
This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer.
Study for people undergoing DIEP flap reconstruction
The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap).
People with a BRCA1 or BRCA2 mutation
This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers.
Additional Results on Clinicaltrials.gov Prevention, Detection & Risk + Breast Cancer + Risk Reduction
UCLA Breast Cancer Survivor Health Promotion Research Study
NCT ID: NCT05113485 (https://classic.clinicaltrials.gov/show/NCT05113485)
Protocol for Women at Increased Risk of Developing Breast Cancer
NCT ID: NCT00291096 (https://classic.clinicaltrials.gov/show/NCT00291096)
Enhancing Cancer Prevention and Control Pathways-Native Health Initiative
NCT ID: NCT04259762 (https://classic.clinicaltrials.gov/show/NCT04259762)
Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://classic.clinicaltrials.gov/show/NCT04722692)
RANKL Inhibition and Mammographic Breast Density
NCT ID: NCT04067726 (https://classic.clinicaltrials.gov/show/NCT04067726)
Cascade Testing in Families With Newly Diagnosed Hereditary Breast and Ovarian Cancer Syndrome
NCT ID: NCT04009148 (https://classic.clinicaltrials.gov/show/NCT04009148)
Making Informed Choices on Incorporating Chemoprevention Into Care (MiCHOICE)
NCT ID: NCT04496739 (https://classic.clinicaltrials.gov/show/NCT04496739)
Dedicated Breast CT for Quantitative Breast Density Measurements in Mexican-origin Women in Southern Arizona
NCT ID: NCT04799665 (https://classic.clinicaltrials.gov/show/NCT04799665)
The Genomic Medicine at VA Study
NCT ID: NCT04331535 (https://classic.clinicaltrials.gov/show/NCT04331535)
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.